Remove tag value-based-care
article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). The standard of care for the condition includes blood transfusions, hydroxyurea and iron chelation.

FDA 59
article thumbnail

Patient adherence – the key to restoring trust in pharma

pharmaphorum

Given the high price tags placed on many medications, it’s easy to understand why patients often feel that they are being taken advantage of. Finally, the belief that pharmaceutical companies prioritise their bottom lines over the health and well-being of patients is probably the largest contributing factor to lack of trust in the industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A roadmap for adopting New Science 

pharmaphorum

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. New Science is clearly on the rise. However, New Science is more expensive to develop.

article thumbnail

Sanofi offers refunds for Cablivi in novel model for rebates

Pharmaceutical Technology

On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based agreements in a slightly different way. Unlike other contracts, a refund for Cablivi depends on individual clinical outcomes compared to more commonly used population-based outcomes.

article thumbnail

Realising milestones with gene therapy for SMA

European Pharmaceutical Review

This is often called an ‘SMN-based’ or ‘SMN-enhancing’ approach. 3 The one-time gene therapy received final draft guidance from the National Institute for Health and Care Excellence (NICE) on 16 March 2023. Transformative treatments have exposed and tested the limitations of our value assessment and reimbursement systems.

FDA 68
article thumbnail

Best Content Ideas for Your Christmas Marketing in Social Media this 2022 – Blog #77

The Social Pharmacist

Then, you induce stronger brand awareness by responding to changing seasons that resonate with your brand’s core identity and values. Simply use pictures or custom graphics that have a mix of images and words conveying your seasonally appropriate value proposition. So, combined goods increase the perceived value of the products.

article thumbnail

Best Content Ideas for Your Christmas Marketing in Social Media this 2022 – Blog #77

The Social Pharmacist

Then, you induce stronger brand awareness by responding to changing seasons that resonate with your brand’s core identity and values. Simply use pictures or custom graphics that have a mix of images and words conveying your seasonally appropriate value proposition. So, combined goods increase the perceived value of the products.